IDEAYA Reports Encouraging Clinical Activity From Darovasertib And Crizotinib Phase 1/2 Trial

IDEAYA Biosciences, Inc. (IDYA) issued a clinical data update for the phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma patients. The preliminary interim data includes: 100% disease control rate; ad 31% overall response rate. The company said these data provide clinical proof-of-concept for the combination treatment.

IDEAYA noted that it had cash, cash equivalents and marketable securities of approximately $386 million as of September 30, 2021, which it believes will fund its planned operations into 2025.

Shares of IDEAYA Biosciences were up 2% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retail giant Walmart is set to expand its drone delivery network to 34 sites across six states in the U.S. by the end the year through its partnership with drone delivery company DroneUp. The deliveries will reach about 4 million U.S. households in Arizona, Arkansas, Florida, Texas, Utah and Virginia. Blue Moose of Boulder LLC recalled one lot of 7 oz units of its "Spinach Artichoke Parmesan Dip" for potentially containing undeclared tree nut (Cashew) and soy allergens, the U.S. Food and Drug Administration or FDA said in a statement. The recall was initiated due to mislabeling issue where a small run Spinach Artichoke Cashew Dip was labeled as Spinach Artichoke Parmesan Dip. Samsung Electronics announced that Google Assistant will be available for Galaxy Watch4 starting Tuesday. The South Korean electronics major has entered into partnership with Google to build a unified Wear OS platform for a seamless connection across Android devices. Starting Tuesday, Google Assistant will be available in 10 markets.
Follow RTT